Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03271372 · ClinicalTrials.gov registry record · Phase 3
Adjuvant Avelumab in Merkel Cell Cancer
A Phase 3 study of Stage III Merkel Cell Carcinoma AJCC v8 and Stage IIIB Merkel Cell Carcinoma AJCC v8, sponsored by University of Washington.
- Active
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
- 9
- Study locations
NCT03271372 is a Phase 3 study of Stage III Merkel Cell Carcinoma AJCC v8 and Stage IIIB Merkel Cell Carcinoma AJCC v8 that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 101 participants. The trial reports 9 study locations across 9 states.
The verdict
NCT03271372, a Phase 3 study of Stage III Merkel Cell Carcinoma AJCC v8 and Stage IIIB Merkel Cell Carcinoma AJCC v8, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
- 9
- Study locations
Study Summary
This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery and/or radiation therapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Avelumab
- OTHER Peripheral Blood Collection
Study Locations (9)
California
- University of California Irvine Chao Family Comprehensive Cancer Center - Orange
Colorado
- University of Colorado Cancer Center University of Colorado Anschutz Medical Campus - Aurora
Florida
- Moffitt Cancer Center - Tampa
Illinois
- Northwestern University - Chicago
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- University of North Carolina Lineberger Comprehensive Cancer Center - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2017-12-19 |
| Est. Completion | 2029-02-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03271372
The ClinicalTrials.gov registry entry for NCT03271372 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stage III Merkel Cell Carcinoma AJCC v8 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03271372 reports 9 study locations spanning 9 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT03271372 about?
NCT03271372 is a clinical study titled "Adjuvant Avelumab in Merkel Cell Cancer". This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery and/or radiation therapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack th...
What is the current status of trial NCT03271372?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2017-12-19. Estimated completion is 2029-02-18.
What conditions does trial NCT03271372 study?
This clinical trial studies the following conditions: Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8.
What interventions are being tested in trial NCT03271372?
The interventions under investigation include: Placebo (OTHER), Avelumab (DRUG), Peripheral Blood Collection (OTHER).
Who is sponsoring clinical trial NCT03271372?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03271372 being conducted?
This trial has 9 study locations across California, Colorado, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Stage III Merkel Cell Carcinoma AJCC v8
All registered trials for this condition
Stage IIIB Merkel Cell Carcinoma AJCC v8
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.